Search

Your search keyword '"Orfi, L"' showing total 147 results

Search Constraints

Start Over You searched for: Author "Orfi, L" Remove constraint Author: "Orfi, L"
147 results on '"Orfi, L"'

Search Results

15. Pharmacophore and Binding Analysis of Known and Novel B-RAF Kinase Inhibitors

17. Developing FGFR4 Inhibitors As Potential Anti-Cancer Agents Via In Silico Design, Supported by In Vitro and Cell-Based Testing

18. Developing FGFR4 Inhibitors As Potential Anti-Cancer Agents Via In Silico Design, Supported by In Vitro and Cell-Based Testing

19. Delivery of the p38 MAPkinase inhibitor SB202190 to angiogenic endothelial cells: development of novel RGD-equipped and PEGylated drug-albumin conjugates using platinum(II)-based drug linker technology

20. Delivery of the p38 MAPkinase inhibitor SB202190 to angiogenic endothelial cells: development of novel RGD-equipped and PEGylated drug-albumin conjugates using platinum(II)-based drug linker technology

21. Rational Design of RGD-albumin conjugates for targeted delivery of the VEGF-R kinase inhibitor PTK787 to angiogenic endothelium

22. Novel, Selective CDK9 Inhibitors for the Treatment of HIV Infection

24. Signalling Inhibitors Against Mycobacterium tuberculosis – Early Days of a New Therapeutic Concept in Tuberculosis

28. Interaction of nilotinib, dasatinib and bosutinib with ABCB1 and ABCG2: implications for altered anti-cancer effects and pharmacological properties.

29. Protein Kinase Cξ Drives Sphingomyelin Metabolism in the Nucleus During Cell Proliferation

30. Inhibition of c-Met with the Specific Small Molecule Tyrosine Kinase Inhibitor SU11274 Decreases Growth and Metastasis Formation of Experimental Human Melanoma

31. Acid−Base Profiling of Imatinib (Gleevec) and Its Fragments

37. Flk-1 as a target for tumor growth inhibition

39. HER2 Mediates PSMA/mGluR1-Driven Resistance to the DS-7423 Dual PI3K/mTOR Inhibitor in PTEN Wild-type Prostate Cancer Models.

40. Lyophilization and homogenization of biological samples improves reproducibility and reduces standard deviation in molecular biology techniques.

42. Mito-oncology agent: fermented extract suppresses the Warburg effect, restores oxidative mitochondrial activity, and inhibits in vivo tumor growth.

43. Regulation of influenza A virus mRNA splicing by CLK1.

44. Machine learning and docking models for Mycobacterium tuberculosis topoisomerase I.

45. Nox4 contributes to the hypoxia-mediated regulation of actin cytoskeleton in cerebrovascular smooth muscle.

46. Development of a 3D Tissue Culture-Based High-Content Screening Platform That Uses Phenotypic Profiling to Discriminate Selective Inhibitors of Receptor Tyrosine Kinases.

47. Small Molecule Inhibition of ERK Dimerization Prevents Tumorigenesis by RAS-ERK Pathway Oncogenes.

48. Anticytolytic screen identifies inhibitors of mycobacterial virulence protein secretion.

49. NADPH oxidase 4 is expressed in pulmonary artery adventitia and contributes to hypertensive vascular remodeling.

50. Synthesis and evaluation of phosphorus containing, specific CDK9/CycT1 inhibitors.

Catalog

Books, media, physical & digital resources